Brief: Kura Oncology's Menin Inhibitor Ziftomenib Selected For The Leukemia & Lymphoma Society'S Pediatric Acute Leukemia Master Clinical Trial

Kura Oncology

08/12/2023 13:31

Dec 8 (Reuters) - Kura Oncology Inc  KURA.O :
    * KURA ONCOLOGY’S MENIN INHIBITOR ZIFTOMENIB SELECTED FOR
THE
LEUKEMIA & LYMPHOMA SOCIETY’S PEDIATRIC ACUTE LEUKEMIA (PEDAL)
MASTER CLINICAL TRIAL
    * KURA ONCOLOGY INC - LLS AND PRINCESS MÁXIMA CENTER WILL
SPONSOR
PHASE 1 STUDY OF ZIFTOMENIB IN PEDIATRIC PATIENTS WITH ACUTE
LEUKEMIAS
    * KURA ONCOLOGY INC - KURA WILL SUPPLY LLS AND PRINCESS
MÁXIMA
CENTER WITH ZIFTOMENIB FOR STUDY

Source text for Eikon:  ID:nGNXb5t26M 
Further company coverage:  KURA.O 

 ((reuters.briefs@thomsonreuters.com;))